Skin Microbiome Transplantation in Dermatology: Current Evidence and Clinical Perspectives

Abstract

Skin microbiome transplantation (SMT) is an innovative approach in dermatology aimed at restoring microbial homeostasis to treat various cutaneous disorders. Growing evidence from translational and clinical studies highlights the potential of SMT to modify disease outcomes in conditions characterized by dysbiosis, such as atopic dermatitis, psoriasis, and acne. This review provides a comprehensive overview of SMT, including epidemiological insights, mechanistic underpinnings, risk factors, clinical features, diagnostic advancements, and therapeutic applications. Recent advances, emerging therapies, and consensus guideline recommendations are discussed, offering clinicians a detailed understanding of SMT's role in contemporary dermatological practice.

Introduction

The human skin harbors a diverse and dynamic community of microorganisms, collectively known as the skin microbiome. This ecosystem plays a vital role in maintaining cutaneous homeostasis, modulating immune responses, and protecting against pathogenic colonization. Disruption of the skin microbiome termed dysbiosis has been implicated in the pathogenesis of multiple dermatological diseases. Traditional therapies often target symptoms or inflammation, but do not address underlying microbial imbalances. Skin microbiome transplantation, modeled after fecal microbiota transplantation in gastroenterology, introduces healthy microbial communities to restore equilibrium. This concept is rapidly evolving, with mounting scientific support for its potential to revolutionize the management of chronic skin conditions.

Epidemiology / Disease Burden

Chronic skin disorders associated with microbiome dysbiosis, such as atopic dermatitis, psoriasis, and acne vulgaris, affect millions globally and contribute substantially to morbidity, psychosocial burden, and healthcare costs. Atopic dermatitis alone impacts up to 20% of children and 3% of adults worldwide. The increasing prevalence of these conditions parallels shifts in environmental exposures, urbanization, and antibiotic use, all of which influence the skin microbiome. Understanding the epidemiological trends and disease burden underscores the urgent need for novel, microbiome-targeted interventions like SMT.

Pathophysiology

The skin microbiome comprises bacteria, fungi, viruses, and mites, residing in distinct niches influenced by anatomical site, host genetics, and environmental factors. Disruption of this delicate balance can lead to pathogenic overgrowth or loss of protective commensals, triggering or exacerbating inflammatory skin diseases. For example, Staphylococcus aureus dominance is commonly observed in atopic dermatitis flares, while Cutibacterium acnes dysregulation is implicated in acne. SMT aims to correct dysbiosis by reintroducing a diverse, healthy microbial community, thereby restoring immune tolerance, barrier function, and pathogen resistance. Mechanistic studies suggest that transplanted microbes modulate host immunity via short-chain fatty acid production, antimicrobial peptide induction, and competitive inhibition of pathogens.

Risk Factors

Risk factors for skin microbiome dysbiosis include genetic predisposition, altered skin barrier (e.g., filaggrin mutations), frequent antibiotic use, excessive hygiene practices, environmental pollutants, and underlying medical conditions such as immunodeficiency. Hospitalization, use of topical steroids, and chronic wounds also predispose individuals to microbial imbalance. Understanding these risk factors is crucial for identifying candidates who may benefit most from SMT and for developing preventive strategies alongside therapeutic interventions.

Clinical Features

Clinical manifestations of microbiome-driven skin disorders vary widely but may include erythema, pruritus, scaling, pustulation, and chronic relapsing lesions. In atopic dermatitis, for instance, acute flares correspond to increased S. aureus colonization and decreased microbial diversity. Psoriasis patients may display altered Firmicutes to Actinobacteria ratios, while acne is characterized by C. acnes phylotype shifts. Recognizing these features can aid clinicians in suspecting underlying dysbiosis and considering SMT in refractory cases.

Diagnosis

Diagnosis of skin microbiome-related conditions traditionally relies on clinical assessment and, when indicated, microbiological cultures. However, advanced techniques such as 16S rRNA gene sequencing and metagenomic shotgun sequencing have revolutionized the characterization of cutaneous microbial communities. These molecular diagnostics enable precise identification of dysbiotic patterns, monitoring of microbial shifts post-SMT, and stratification of patients for targeted therapies. Incorporation of such tools into dermatological practice enhances diagnostic accuracy and informs personalized treatment approaches.

Treatment & Management

Conventional treatments for microbiome-associated skin disorders include topical and systemic antibiotics, corticosteroids, and immunomodulators, which may further disrupt microbial balance. SMT offers a paradigm shift by directly restoring microbial homeostasis. The procedure involves sourcing microbiota from healthy donors, processing and applying it via topical formulations, sprays, or dressings to affected sites. Early-phase clinical trials have demonstrated safety and feasibility, with some studies reporting reduced disease severity and relapse rates in atopic dermatitis and acne. Adjunctive strategies such as prebiotics, synbiotics, and barrier repair agents may enhance SMT efficacy.

Recent Advances / Emerging Therapies

Recent advances in SMT research include the development of standardized donor screening protocols, optimization of delivery vehicles (e.g., hydrogels, bioactive dressings), and utilization of defined microbial consortia for targeted reconstitution. Synthetic biology approaches are being explored to engineer commensals with enhanced therapeutic properties. Furthermore, ongoing randomized controlled trials are assessing the long-term safety, efficacy, and durability of SMT across various dermatological conditions. These innovations are paving the way for regulatory approval and broader clinical adoption.

Guideline Recommendations

While SMT remains investigational, expert consensus and interim guidelines emphasize the importance of rigorous donor selection, informed consent, and post-procedural monitoring. The use of SMT should be restricted to research settings or specialized centers until larger, high-quality trials validate its clinical benefits and risk profile. Current guidelines advocate for adjunctive use of SMT in refractory cases and recommend integration with conventional therapies to optimize outcomes. Ongoing updates from dermatological societies are anticipated as new evidence emerges.

Conclusion

Skin microbiome transplantation represents a promising frontier in the management of dermatological diseases driven by microbial dysbiosis. Early clinical data suggest favorable outcomes, but further research is required to refine protocols, establish efficacy, and delineate patient selection criteria. As our understanding of the skin microbiome deepens, SMT has the potential to become a cornerstone of personalized dermatological therapy, offering hope for patients with treatment-resistant conditions.